That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Leqembi is a dual-acting monoclonal antibody designed to target and ablate amyloid beta aggregates that are a major driver of ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...

Leqembi is a monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta in the treatment of Alzheimer’s disease. The medication was tested in numerous clinical trials ...

In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the ...